Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback